EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C12H16ClN3O3S |
| Net Charge | 0 |
| Average Mass | 317.798 |
| Monoisotopic Mass | 317.06009 |
| SMILES | Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O |
| InChI | InChI=1S/C12H16ClN3O3S/c1-8-10(19-7-11-14-5-6-15-11)4-3-9(13)12(8)16-20(2,17)18/h3-4,16H,5-7H2,1-2H3,(H,14,15) |
| InChIKey | FOYWMEJSRSBQGB-UHFFFAOYSA-N |
| Roles Classification |
|---|
| Biological Role: | alpha-adrenergic agonist An agent that selectively binds to and activates α-adrenergic receptors. |
| Application: | alpha-adrenergic agonist An agent that selectively binds to and activates α-adrenergic receptors. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| dabuzalgron (CHEBI:142452) has role α-adrenergic agonist (CHEBI:35569) |
| dabuzalgron (CHEBI:142452) is a aromatic ether (CHEBI:35618) |
| dabuzalgron (CHEBI:142452) is a imidazoles (CHEBI:24780) |
| dabuzalgron (CHEBI:142452) is a monochlorobenzenes (CHEBI:83403) |
| dabuzalgron (CHEBI:142452) is a sulfonamide (CHEBI:35358) |
| IUPAC Name |
|---|
| N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide |
| INNs | Source |
|---|---|
| dabuzalgrón | WHO MedNet |
| dabuzalgronum | WHO MedNet |
| dabuzalgron | WHO MedNet |
| dabuzalgron | WHO MedNet |
| Synonym | Source |
|---|---|
| Ro 115-1240 | SUBMITTER |
| Manual Xrefs | Databases |
|---|---|
| EP0887346 | Patent |
| Registry Numbers | Sources |
|---|---|
| Reaxys:13257747 | Reaxys |
| CAS:219311-44-1 | ChemIDplus |
| Citations |
|---|